Andrew Sheets: The U.S. Dollar and Cross-Asset Portfolios

Andrew Sheets: The U.S. Dollar and Cross-Asset Portfolios

With many investors predicting the U.S. dollar to continue to weaken, its potential for diversification and high yields may indicate otherwise.


----- Transcript -----

Welcome to Thoughts on the Market. I'm Andrew Sheets, Chief Cross-Assets Strategist for Morgan Stanley. Along with my colleagues bringing you a variety of perspectives, I'll be talking about trends across the global investment landscape and how we put those ideas together. It's Tuesday, April 25th at 2 p.m. in London.


The U.S. dollar has fallen about 11% from its highs last September. We think a majority of investors expect that weakness to continue, driven by factors ranging from expensive valuations to potential slowing of the U.S. economy, to the view that a more fragmented geopolitical backdrop will lead to less trade and transactions in U.S. dollars.


In contrast, our foreign exchange strategists think it's more likely that the dollar strengthens. I want to discuss the idea of dollar strength from a larger lens and what it could mean for a cross-asset portfolio.


For a multi-asset investor, the greatest appeal of the U.S. dollar comes from its diversification. At present, it is one of the few positive carry diversifiers, which is another way of saying that it's one of the few assets out there that pays you while also acting as a portfolio hedge, thanks to the dollar generally moving in the opposite direction of riskier assets like stocks or high yield bonds.


Importantly, that diversification from the U.S. dollar makes a lot of intuitive sense to us. We think the dollar could do well if U.S. growth is very hot, as investors are drawn to even higher U.S. rates under that scenario, or if growth is very weak as investors seek out safety and liquidity. These extremes in growth, we think, represent two of the key risks, for riskier assets.

In contrast, the dollar probably does weaken if growth is down the middle and a so-called soft landing for the economy. In this case, modest Fed easing without the fear of recession would likely cause investors to seek out cheaper, more volatile currencies. But this soft landing scenario is probably the best outcome for the riskier other parts of one's portfolio, allowing the dollar to provide diversification as it zigs while other assets zag.


But what about the dollar's higher valuation or the threat of geopolitical shifts? Well, on valuation, our work suggests that it tends to be a pretty weak predictor of foreign exchange returns over the next 6 to 12 months, for better or for worse. And on geopolitical shifts, the dollar remains the dominant currency of global trade. And importantly, over the last year, a year that’s contained quite a bit of geopolitical uncertainty, it's continued to show diversification benefits.


In summary, many investors expect U.S. dollar weakness to continue. Thanks to its high yield and powerful potential for diversification, we think it's more likely to appreciate.


Thanks for listening. Subscribe to Thoughts on the Market on Apple Podcasts, or wherever you listen, and leave us a review. We'd love to hear from you.

Episoder(1514)

Special Episode, Part 2: Coronavirus - Building Models to Rebuild Economies

Special Episode, Part 2: Coronavirus - Building Models to Rebuild Economies

When do we return to work? The market reaction? The drug pipeline? Chief Cross-Asset Strategist Andrew Sheets and Head Biotech Equity Analyst Matthew Harrison continue their discussion on the impact of the Covid-19 pandemic.

14 Apr 202010min

Mike Wilson: U.S. Markets React to Fed Moves

Mike Wilson: U.S. Markets React to Fed Moves

If there is one lesson to be learned from the financial repression era it's that when risk premium appears, investors may want to make moves before it evaporates.

13 Apr 20204min

Special Episode: Coronavirus – Building Models to Rebuild Economies

Special Episode: Coronavirus – Building Models to Rebuild Economies

How do you track a virus, a global economy and a road to recovery? On this special episode, an engaging conversation with our Chief Cross-Asset Strategist and Head Biotech Equity Analyst.

9 Apr 20209min

Michael Zezas: Another Dose of Fiscal Stimulus?

Michael Zezas: Another Dose of Fiscal Stimulus?

The U.S. Congress has been debating ways to flatten another worrying curve: the sliding economic growth curve. What form could additional fiscal stimulus take?

8 Apr 20202min

Mike Wilson: What Are Markets Thinking?

Mike Wilson: What Are Markets Thinking?

Asset prices often reflect the obvious before it becomes obvious. So the question for investors now is, "What is the market thinking about that's not obvious?"

6 Apr 20203min

Andrew Sheets: Optimism for Credit Markets

Andrew Sheets: Optimism for Credit Markets

Even as economic and public health data get worse, recent changes in three key factors make global credit markets an attractive option. Our Chief Cross-Asset Strategist, Andrew Sheets, explains.

3 Apr 20202min

Michael Zezas: What Does the CARES Act Buy?

Michael Zezas: What Does the CARES Act Buy?

The $2 trillion CARES Act includes a variety of provisions that will help preserve the financial health of state and local governments, hospitals and airports. Here’s what’s inside.

1 Apr 20202min

Mike Wilson: U.S. Equities - Is the Worst Behind Us?

Mike Wilson: U.S. Equities - Is the Worst Behind Us?

Although economic and earnings data could be gloomy over the next month, have equity markets already discounted the bad news? Detailed analysis from Chief Investment Officer Mike Wilson.

30 Mar 20203min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
lydartikler-fra-aftenposten
rss-borsmorgen-okonominyhetene
livet-pa-veien-med-jan-erik-larssen
rss-vass-knepp-show
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
utbytte
pengepodden-2
okonomiamatorene
morgenkaffen-med-finansavisen
aksjepodden
lederpodden
rss-markedspuls-2
rss-fri-kontantstrom
rss-impressions-2
stormkast-med-valebrokk-stordalen